ASIA-PACIFIC VACCINES EXCELLENCE AWARDS (AVEA) 2022
Asia-Pacific Vaccine Excellence Awards (AVEA) 2022 seeks to recognize the Asian vaccine manufacturing community and the achievements it has made over the past year. The industry has displayed resilience and innovation in the face of the COVID pandemic and the needs of the vaccine rollout, and continues with R&D excellence. The purpose of AVEA2022 is to recognize the outstanding achievements of vaccine & supply chain experts, organizations, and the newest technologies in Asia. Featuring top vaccine industry leaders, along with the latest advances in technologies and best practices in R&D and manufacturing, the Asia Pacific Vaccine Excellence Award applauds extraordinary leaders & trendsetters of today and inspires the innovators of tomorrow. The Awards Ceremony will be held in conjunction with the 4th Annual Vaccines World Asia Congress 2022 Virtual Conference, which will be held from 9-10 November 2022.
How does it work?
IMAPAC, the organizing committee of AVEA 2022 has called for nomination from IMAPAC vaccines community for different vaccine award categories. All entries and nominations were considered and submitted to the judging panel and market research team from IMAPAC. Based on the number of nominations and assessment, the top 5 entries under each category were shortlisted. From the top 5 entries, the award winner will be determined by 100 % voting results from the public or bioprocessing community.
TIMELINE OF AWARDS
Criteria for nomination
THE CRITERIA FOR A COMPANY TO BE ELIGIBLE FOR THE ASIA PACIFIC VACCINE EXCELLENCE AWARDS 2022 ARE:
- The company should be an organization that is involved in biopharmaceutical development and/or manufacturing with a notable presence in APAC.
- The company should have displayed significant developments in the past few years